Promomed Group has replenished its portfolio with a new drug for the treatment of HIV infection

Sfumata, a medicine for HIV infection, received marketing authorization certificate, becoming the second drug in the antiretroviral portfolio of Promomed Group.

The development and production of drugs for the treatment of major global diseases, including the human immunodeficiency virus is one of the most important strategic directions in the activities of Promomed Group focused on solving significant medical problems, saving and significantly improving the quality of life of patients.

«To stop the HIV epidemic is only possible through the joint efforts of representatives of science, medicine and pharmaceutical market, so our company does not stand aside. Antiviral therapy is the key to success in the treatment of patients with HIV infection, it helps to increase the life expectancy and maintain the quality of life of patients. The launch of the new drug is an important step forward for Promomed on the path to developing a line of drugs for HIV,» commented Kira Zaslavskaya, Director for New Products at Promomed Group.

Sfumata (atazanavir) belongs to the class of protease inhibitors (PIs) and acts by blocking the HIV protease. The drug differs from other protease inhibitors in that it more rarely causes abnormal changes in adipose tissue, thereby reducing the likelihood of lipodystrophy in patients. It is one of the preferred drug products for the treatment of HIV infection in pregnant women, as it is one of the most studied and safe PIs during pregnancy in cases where the potential benefit to the mother outweighs the potential risk to the fetus.

This drug product is included in the WHO Model List of Essential Medicines, and is also included in the List of Vital and Essential Drugs in Russia.

Sfumata will be available in 150, 200 and 300 mg capsules convenient for approved dosing schedules.